IGF-1 LR3(1mg)

65,00 €

CHEMICAL PROPERTIES

Property	Specification
Molecular weight	~9110 g/mol
CAS	946870-92-4
Chemical formula	Not fully defined; may vary depending on synthesis and formulation
Peptide length	83 amino acids
Structure	Linear peptide containing disulfide bonds similar to native IGF-1
Amino acid sequence	Modified peptide consisting of IGF-1 (70 amino acids) with an additional 13-amino-acid N-terminal extension and Arg³ substitution: NH₂-Ala-Ser-Cys-Gly-Pro-Cys-Lys-Ser-Gln-Ser-Cys-Phe-Val-His-Leu-Cys-Pro-Glu-Ile-Tyr-Cys-His-Ser-Gly-Pro-Ser-Gly-Ser-Thr-Glu-Glu-Ser-Leu-Pro-Ser-Gln-Gly-Val-Val-Gly-Ser-Ile-Ala-Leu-Ala-Gly-Ile-Cys-Gly-Ser-Ser-Ile-Ser-Asn-Gly-Cys-His-Lys-Gly-Ala-Pro-Pro-Lys
Solubility	Soluble in aqueous solutions at neutral or slightly acidic pH
Form	Lyophilized powder
Vial Content	1mg Total
Purity	≥98% (HPLC), confirmed by analytical testing

Availability: 4 in stock

Description
Reviews (0)

1. PRODUCT SUMMARY

IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor 1 with an extended amino acid sequence. The modification includes a substitution at position 3 (Arg instead of Glu) and the addition of a 13-amino-acid N-terminal extension, which reduces binding affinity to IGF-binding proteins (IGFBPs) and increases receptor availability. IGF-1 LR3 is used in scientific research to investigate cellular processes such as proliferation, differentiation, and metabolic regulation, particularly through activation of IGF-1 receptor signaling pathways.

2. STORAGE PROTOCOL

Lyophilized State: Store long-term at -20°C (-4°F). Ensure the vial remains hermetically sealed and shielded from UV exposure.

Reconstituted Solution: Once reconstituted with a sterile diluent, the product must be kept refrigerated at 2–8°C (36–46°F).

Usage Window: For optimal experimental integrity, utilize the reconstituted solution within 30 days. Avoid repeated freeze-thaw cycles or high-speed vortexing.

3. RESEARCH APPLICATIONS

IGF1R Signaling Pathways: Investigating receptor-mediated mechanisms and their influence on cellular growth and proliferation.

Cellular Development & Differentiation: Studying the processes of cell maturation and the regulation of tissue-specific differentiation.

Intracellular Metabolic Mapping: Evaluating the activation of key signaling pathways, including PI3K/AKT, in metabolic regulation.

Binding Protein Interactions: Researching the structural interactions between the peptide and IGF-binding proteins (IGFBPs) in experimental models.

4. REGULATORY DISCLAIMER

NOTICE: This product is supplied strictly for laboratory research and development. It is STRICTLY NOT FOR HUMAN CONSUMPTION, nor is it intended for any clinical, therapeutic, medical, or diagnostic procedures. Use must be restricted to qualified scientific professionals in a controlled environment. This product is not designed to diagnose, treat, or prevent any medical condition.

5. REFERENCES

Insulin-like Growth Factor-I (IGF-I) and Long R3 IGF-I in early embryonic development
https://pubmed.ncbi.nlm.nih.gov/11181549
Effects of insulin and insulin-like growth factor-I and LR3 IGF-I on protein metabolism
https://pmc.ncbi.nlm.nih.gov/articles/PMC1137054
Insulin-like growth factor-I analogue LR3 IGF-I attenuates loss of lean tissue in rats
https://pubmed.ncbi.nlm.nih.gov/11472075
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling
https://pubmed.ncbi.nlm.nih.gov/39610283
IGF-1 LR3 treatment in fetal growth restriction models
https://pubmed.ncbi.nlm.nih.gov/39679943
Role of IGF1-LR3 in glucose uptake and IGFBP interaction
https://pmc.ncbi.nlm.nih.gov/articles/PMC5750484